| 标题 |
Safety, tolerability, and preliminary efficacy results of a phase 1 study of LB2102, a dnTGFβRII armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) |
| 网址 | |
| DOI | |
| 其它 |
期刊:Journal of Clinical Oncology 作者:Jacob Sands; Alberto Chiappori; Ben C. Creelan; Paul Otto Schwarzenberger; Mythili Koneru; et al 出版日期:2025-05-28 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)